Green Mountain Coffee Earnings Start Stock Price Swinging

Source: courtesy Green Mountain Coffee Roasters Inc.Green Mountain Coffee Roasters Inc. (NASDAQ: GMCR) reported fourth fiscal quarter and full-year 2013 earnings after markets closed Thursday. For the quarter, the maker of the Keurig single-cup brewing system posted adjusted diluted earnings per share (EPS) of $0.89 on revenues of $1 billion. In the same period a year ago, the company reported EPS of $0.64 on revenues of $946.7 million.Fourth-quarter results compare to the Thomson Reuters consensus estimates for EPS of $0.75 and $964.56 million in revenues.

For the full year, adjusted EPS totaled $3.39 on revenues of $4.36 billion, compared with EPS of $2.40 on revenues of $3.86 billion in fiscal 2012. The consensus estimate had called for EPS of $3.25 on revenues of $4.28 billion.

Green Mountain reported that it sold 10.6 million Keurig systems during the fiscal year, up from 9.2 million in 2012. Sales of its single portion packs rose 18% for the full year and the only dim spot in the report was that other products and royalties revenues were down 12%. Gross margin rose from 32.9% in 2012 to 37.2% in 2013.

For the 2014 fiscal year Green Mountain expects sales growth in the high single digits with more of the growth coming in the second half of the year. Adjusted EPS is forecast at $3.75 to $3.85. The consensus estimates call for revenue of $4.69 billion and EPS of $3.78. The company's revenue estimate is lower than expected and that will hurt the share price when markets open on Thursday.

For the first quarter of its new fiscal year Green Mountain expects year-over-year sales growth in the low-to-mid single digits and adjusted EPS in a range of $0.85 to $0.90. The consensus estimates call for revenue of $1.44 billion and EPS of $0.96. Again the company's forecast is weaker than expected.

Last August, Green Mountain told investors that unlicensed products compatible with the company's Keurig system won't take more than 5% of sales this year and no more than 15% in two or three years. An independent scanner tracking company reported that 16% of the single-cup industry's sales are now made by unlicensed vendors. Green Mountain is forecasting more revenue from licensing next year, but that isn't going to be enough to overcome the lost sales, at least not if the revenue forecasts are accurate.

Hot Medical Companies To Own For 2014

The company's shares are up about 2% in after-hours trading today, at $63.30 in a 52-week range of $27.54 to $89.66. Shares fell immediately after the earnings results were posted and have now swung back to a gain. The consensus target price for the shares was around $91.80 before today's report.

Car insurance is cheapest in December - Study

NEW YORK (CNNMoney) Shopping for car insurance? You may want to check the calendar first.

That's the takeaway from a yearlong study released Thursday by InsuranceQuotes.com, which found that the cost of car insurance can vary by up to 48% depending on what month it's purchased.

Nationally, December was the most affordable month to buy, with coverage 8% cheaper on average than policies purchased in March, the most expensive month.

The price swings were much larger in many individual states. In Hawaii, it was 48% cheaper to buy in December than in March, the study found; in Pennsylvania, December was 34.5% cheaper than the most expensive month, April.

  Tiny cars flunk crash test

Researchers said they couldn't identify any single factor driving the variability. Complicating matters was the fact that the patterns vary across states; although December was the cheapest month nationally on average, it was the most expensive month in 11 individual states.

This is the first year the study has been conducted, and InsuranceQuotes senior analyst Laura Adams said it's "very difficult at this point to take away any patterns."

"There are multiple factors that make rates variable," she said. "We can't pinpoint any one."

Varied pricing patterns in different states are to be expected since insurance is regulated at the state level, analysts said. In addition, since climates vary by region, carriers in different states experience surges in weather-related claims that can raise costs at different times.

December is likely the cheapest month in many places because rate increases and inflation adjustments often take effect once the new year begins in January.

Adams said the findings underscore the importance of shopping around and looking out for better deals than the one you've got. InsuranceQuotes has a free calculator on its website to help drivers evaluate their options.

"Rates are constantly changing, much more so than the average consumer would realize," Adams said.

Mid-Afternoon Market Update: Markets Green Despite Disappointing Apple Report

Toward the end of trading Tuesday, the Dow traded up 0.59 percent to 15,928.49 while the NASDAQ gained 0.22 percent to 4,092.53. The S&P also rose, gaining 0.58 percent to 1,791.91.

Top Headline
Ford Motor Co (NYSE: F) reported a rise in its fourth-quarter profit. Ford's quarterly profit surged to $3.04 billion, or $0.74 per share, from a year-ago profit of $1.60 billion, or $0.40 per share. Its adjusted earnings came in at $0.31 per share. Its revenue surged to $37.6 billion versus $36.3 billion. However, analysts were expecting a profit of $0.28 per share on revenue of $34.96 billion. For 2014, Ford projects a pretax profit of $7 billion to $8 billion.

Equities Trading UP
AK Steel Holding (NYSE: AKS) gained 17.86 percent to $7.06 after the company crushed analyst estimates on the bottom line while narrowly beating on the top line in its fourth quarter report.

Shares of Oshkosh (NYSE: OSK) got a boost, shooting up 7.96 percent to $55.55 after the companyposted upbeat fiscal first-quarter earnings and lifted its full-year forecast.

Silicon Motion Technology (NASDAQ: SIMO) was also up, gaining 14.72 percent to $17.07 after the company reported upbeat Q4 results and issued strong FY14 revenue forecast.

Equities Trading DOWN
Shares of Rent-A-Center (NASDAQ: RCII) were down 21.51 percent to $24.51 on Q4 results.

Apple (NASDAQ: AAPL) shares tumbled 7.80 percent to $507.55 after the company issued weak sales forecast for the second quarter and reported downbeat holiday iPhone sales.

Analysts at BGC Partners downgraded Apple from Buy to Hold.

Corning (NYSE: GLW) was down, falling 6.06 percent to $17.12 after the company reported Q4 results.

Commodities
In commodity news, oil traded up 1.80 percent to $97.44, while gold traded down 0.92 percent to $1,251.80.

Silver traded down 1.26 percent Tuesday to $19.52, while copper fell 0.65 percent to $3.25.

Eurozone
European shares were higher today.

The Spanish Ibex Index surged 1.21 percent, while Italy's FTSE MIB Index gained 0.96 percent.

Meanwhile, the German DAX climbed 0.55 percent and the French CAC 40 surged 0.98 percent while U.K. shares rose 0.34 percent.

Economics
The ICSC-Goldman same-store sales index rose 0.2% in the week ended Saturday versus the earlier week.

The Johnson Redbook Retail Sales Index declined 0.1% in the first three weeks of January versus December.

Orders for durable goods dropped 4.3% in December, versus economists' expectations for a 1.8% gain.

U.S. home prices declined 0.1% in November, according to the S&P/Case-Shiller home price index. However, the index gained 0.9% after seasonal adjustments. Home prices surged 13.7% y/y in November.

The Conference Board's consumer confidence index rose to 80.70 in January, versus a prior reading of 78.10. However, economists were expecting a reading of 78.00.

The Richmond Fed manufacturing index fell to 12.00 in January, from a previous reading of 13.00. However, economists were expecting a reading of 13.00.

The FOMC begins its two-day policy meeting today.

The Treasury is set to auction 2-year notes.

Posted-In: Earnings News Guidance Futures Forex Global Econ #s Economics Intraday Update Markets Movers Tech

(c) 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  Most Popular 5 Ways To Play The Hottest Trend In Cannabis Earnings Expectations For The Week Of January 27: Facebook, Google, Apple And More Why Icahn Is Wrong On Apple ABC's Hulu Strategy Could Cost Disney Millions Of Viewers Apple Down 5% After Q1 Earnings Beat, 51 Million iPhones Sold Five Star Stock Watch: Apple Related Articles (AAPL + AKS) Apple Conference Call Highlights Mid-Day Market Update: Oshkosh Rises After Strong Earnings Report; Apple Shares Tumble Apple TV Will Become a Video Game Console, Sources Say UPDATE: Oppenheimer Reduces Rating on Apple, Down 7 Percent Top Trending Tickers On StockTwits For January 28 ETF Outlook For Tuesday, January 28, 2014 (XLK, AAPL, UNG, SLX, PIO) Around the Web, We're Loving... Lightspeed Trading Presents: Thunder and Tubleweeds: Trading Techniques for the New Market Enviroment Pope Francis Rips 'Trickle-Down' Economics

CBS Earnings Rise Higher Revenues, Share Buybacks

Source: ThinkstockCBS Corp. (NYSE: CBS) reported third quarter 2013 earnings after markets closed Wednesday. For the quarter, the broadcast and cable network posted diluted earnings per share (EPS) of $0.80 on revenues of $3.63 billion. In the same period a year ago, the company reported EPS of $0.60 on revenues of $3.27 billion. Third-quarter results compare to the FactSet consensus estimate for EPS of $0.76 and the Thomson Reuters estimate of $3.47 billion in revenues.

Revenue growth of 11% drove earnings growth of 26%. Content licensing and distribution revenues grew the most, up 18%, and advertising revenues rose 4%. Stock buybacks for the year to date total 39.7 million shares at an average price of $46 a share for a total of $1.84 billion.

CBS attributed part of its earnings growth to the share buyback program and part to growth in operating income. Operating income rose 4% and adjusted diluted EPS grew by 19%, so buybacks represent the largest part of the company's earnings growth. That's one way to keep stockholders happy.

The company's executive chairman said:

CBS’s third quarter proves once again why content is king. Our programming is becoming more valuable all the time as we continue to take advantage of the ever-expanding multiplatform world.

The CEO elaborated:

Through our studio, we have an ownership interest in most of these shows, meaning that their success not only boosts our base business, but also our newer revenue streams as well, including very strong growth in retransmission consent fees, reverse compensation, international sales and all the opportunities afforded to us by exploding advances in technology. Plus, we are working toward a new advertising model in which we get paid for the significant, additional viewing that is increasingly taking place after a show first airs.

Top Blue Chip Companies To Watch For 2015

CBS did not offer guidance in its press announcement, but FactSet estimates fourth-quarter EPS at $0.85 and full-year EPS at $3.09, rising to $3.52 in fiscal 2014.

Shares are down about 1.3% in after-hours trading at $58.86 in a 52-week range of $33.04 to $60.91. The consensus Thomson Reuters price target for the shares was around $63.00 before today's report.

5 Best Cars for Short Drivers

BOSTON (TheStreet) -- Short drivers can sometimes feel like they're in an episode of Little People, Big World when out car shopping, so here are five great models for those of us who look more like Danny DeVito than LeBron James.

"Short drivers obviously have different needs than taller ones," says Warren Clarke of Edmunds, which recently named the Best Cars for Short Drivers for 2013. "The main thing they need is visibility. If you're short and you buy the wrong vehicle, you can end up looking at the car's door instead of out the window."

Clarke says the best models for smaller drivers have low "beltlines" -- the border between a car's metal body and its windows -- and big "greenhouses," the glass area above the frame and below the roof.

He says short drivers should also look for cars with narrower seat cushions, as wide upholstery makes it harder for smaller people to reach a vehicle's pedals comfortably. "People tend to assume that smaller cars are the best choices for smaller drivers, but that's not always true," Clarke says. "Visibility and seat comfort have to do with how a vehicle's cabin has been designed, not necessarily with the car's size." Unfortunately, wider seat cushions often make cars more comfortable for bigger drivers, while higher beltlines and smaller greenhouses tend to look cool -- so more and more automakers seem to favor all three. "There are still models that offer lower beltlines and bigger greenhouses, but you have to specifically look for them," Clarke says. Click below to check out the five lowest-priced such models that Edmunds recommends for shorter drivers (or here for cars the site suggests tall drivers consider). All vehicles listed below appear in order of their manufacturer's suggested retail price for 2013 base models.

Kia Soul

Base price: $14,400

If those cartoon hamsters in Kia's TV commercials for the Soul like this small wagon, shorter human drivers should enjoy it, too.

"It's immediately obvious when you look at that Soul that it's got fairly big greenhouse, with a tall windshield and tall, upright side windows," Clarke says. "Visibility is excellent, and it should be very easy for shorter drivers to see out of the Soul's cabin." Also see: XXXX>> Clarke says the Soul also offers both short and taller drivers a roomy cabin, a modest price and "very good, distinctive styling. It's got that boxy shape that you don't see very often." Under the hood, the 2013 Soul comes standard with a 138-horsepower four-cylinder engine and manual transmission -- a combination that delivers an estimated 25 miles per gallon in the city and 30 mpg on the highway. Another bonus: Kia's industry-leading 10-year/100,000-mile powertrain warranty. You should also look for a completely redesigned 2014 Soul to begin hitting dealer showrooms this fall, starting at $14,700.

Mazda Mazda3

Base price: $16,945

The Mazda3 offers shorter drivers not just great visibility, but great affordability as well.

"This is a really good car to buy if you're on a tight budget, because it's affordable but has great handling," Clarke says. "It's the kind of car that you typically have to pay a lot more money for." And while Edmunds editors like the 2013 Mazda3, a redesigned 2014 version already in Mazda showrooms features a slightly larger and even fancier interior despite an unchanged base price. The 2014 edition also comes standard with a 155-horsepower four-cylinder engine and a manual transmission that team up to produce an impressive 29 mpg/city and 40 mph/highway. Or you can add a six-speed automatic transmission and boost city mileage to 30 mpg.

Volkswagen Passat

Base price: $20,845

This family sedan from Volkswagen features an upscale interior that Clarke says is roomy, but not too big for shorter drivers to safely and comfortably use.

"One of the things I like about the Passat is it has lots and lots of legroom," he says. "It also really feels like you're in a European sedan -- you get a high level of refinement at a really affordable price." Volkswagen is also phasing an improved turbocharged engine into the line, boosting fuel efficiency to 24/mpg city and 35 mpg/highway with a manual transmission. (Automatics get 1 mpg lower highway mileage.) Also see: XXXX>> If that's not "green" enough for you, there's a $26,295 diesel Passat that gets 31 mpg/city and 43 mpg/highway with a manual transmission or 30 mpg/city and 40 mpg/highway with an automatic (technically an "automated manual transmission").

Subaru Forester

Base price: $21,995

"You can just tell by looking at a Forester that its visibility will be excellent for shorter drivers because its greenhouse is huge," Clarke says. "It's got big windows all around."

The Forester also comes standard with all-wheel drive and 8.7-inch ground clearance -- both great for driving either off-road or in bad weather. A redesigned 2014 model already in dealer showrooms also boasts a larger cabin, higher-quality finishes and better transmissions than the 2013 offers despite the same starting price. The changes have added a few miles per gallon to the crossover SUV's fuel efficiency, with a base 2014 Forester now rated at 22 mpg/city and 29 mpg/highway with manual transmission. (The model gets 24 mpg/city and 32 mpg/highway as an automatic.)

Honda Accord

Base price: $21,995

The Accord might not offer the auto industry's most exciting look, but Clarke says the model's big windows make the Honda (HMC) a great choice for shorter drivers.

"The whole greenhouse thing doesn't necessarily lend itself to a sexy-looking car, but it does create a highly functional one because you can see clearly out the windows," he says. "That's certainly true with the Accord." The expert adds that the Accord also boasts a "super-roomy" cabin, good-quality finishes, quick acceleration and sharp handling. The base Accord comes standard with a 185-horsepower four-cylinder engine and a manual transmission that produce a good 24 mpg/city and 34 mpg/highway or 27 mpg/city. (Automatics get 27 mpg/city and 36 mpg/highway.) Environmentalists should also check out the plug-in hybrid Accord that Honda has already rolled out for 2014, or a traditional hybrid that's expected to reach showrooms shortly.

Top 10 Medical Stocks To Buy For 2014

It's interesting. With as much progress as we've made on the biomedical front over the past three decades (we can map DNA, for cryin' out loud), the more we can appreciate the simple things about the human body we didn't know that we didn't know. Enter MetaStat Inc. (OTCBB:MTST). This young company has not only uncovered the telltale signs that a cancer patient's condition is liable to metastasize, but it's even working on a way to stave off metastisization for prone cancer patients.

How can anyone possibly know - let alone prevent - such a thing? It's brilliantly simple.

Inside every cell there are what's called Mena proteins. They're critical to the development of the nervous system as a fetus, though don't play much of a role for a body once that nervous system is developed. They're still there, however, and as MTST has figured out, they can tell a lot about a particular person's likelihood of spreading cancer from one part of the body to another.

Top 10 Medical Stocks To Buy For 2014: Dyadic International Inc (DYAI.PK)

Dyadic International, Inc. (Dyadic), incorporated in September 2002, is a holding company. The Company is a global biotechnology company. The Company has operations at the United States and the Netherlands. Dyadic uses its technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture and sale of enzymes and proteins for the bioenergy, industrial enzyme, and biopharmaceutical industries. The Company derives all of its revenues from the licensing of its technologies, the sale of its enzymes and conducting research and development (R&D) activities for third parties. The Company operates in two segments: the United States operations and The Netherlands operations. The United States segment includes a subsidiary in Poland.

The United States operating segment is a developer, manufacturer and distributor of enzyme products, proteins, peptides and other bio-molecules derived from genes and a collaborat ive licensor of enabling technologies for the development and manufacturing of biological products and use in R&D. The Netherlands operating segment is also a researcher and developer of enzyme products, proteins, peptides and other bio-molecules derived from genes and, to date, has mainly invested in R&D activities.

Dyadic�� R&D activities focus on its fungal strains and associated technologies. Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes. Dyadic manufactures and sells liquid and dry enzyme products to global customers for use within the animal feed, pulp and paper, starch and alcohol, food and brewing, textiles, and biofuels industries.

Dyadic also utilizes a technology platform based on its patented and C1 fungus (the C1 Platform Technology), which enables the development and manufacture of proteins and enzymes for diverse market opportunities. The C1 Platform Technology can also be used to scr een for the discovery of novel genes and proteins. The C1 ! Pl! atform Technology also has the potential of developing and producing other biological products such as antibodies, vaccines, proteins and polypeptides for the biopharmaceutical industry.

Top 10 Medical Stocks To Buy For 2014: Organovo Holdings Inc (ONVO)

Organovo Holdings, Inc. (Organovo), formerly Real Estate Restoration & Rental, Inc., incorporated in 2007, is a development-stage company. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. On December 28, 2011, Real Estate Restoration and Rental, Inc.�� (RERR) entered into an Agreement and Plan of Merger, pursuant to which RERR merged with its, wholly owned subsidiary, Organovo (Merger Sub). On February 8, 2012, the Company merged with and into Organovo Acquisition Corp. (Acquisition Corp.), a wholly owned subsidiary of Organovo, with the Company surviving the merger as a wholly owned subsidiary of Organovo Holdings (the Merger). As a result of the Merger, Organovo acquired the business of Organovo, Inc.

The Company has collaborative research agreements with Pfizer, Inc. (Pfizer) and United Therapeutic Corporation (Unither). As of March 31, 2012, it has five federal grants, including Small Business Innovation Research grants and developed the NovoGen MMX Bioprinter (its first-generation 3D bioprinter). The Company is engaged in the development of specific 3D human tissues to aid Pfizer in discovery of therapies in two areas of interest. In addition, in October 2011, it entered into a research agreement with Unither to establish and conduct a research program to discover treatments for pulmonary hypertension using its NovoGen MMX Bioprinter technology. Additionally, under the research agreement with Unither, the Company granted Unither an option to acquire from the Company a worldwide, royalty-bearing license in certain intellectual property created under the research agreement solely for use in the treatment or prevention of pulmonary hypertension and all other lung diseases.

The Company�� NovoGen MMX Bioprinter is an automate! d device that enables the fabrication of three-dimensional (3D) living tissues comprised of mammalian cells. A custom graphic user interface (GUI) facilitates the 3D design and execution of scripts that direct precision movement of the dispensing heads to deposit cellular building blocks (bio-ink) or supporting hydrogel. The Company is using a third party manufacturer, Invetech Pty., of Melbourne, Australia, to manufacture its NovoGen MMX Bioprinter. Its bioprinting technology and surrounding intellectual property and commercial rights serve as a platform for product generation across multiple markets that employ cell- and tissue-based products and services.

The Company competes with Organogenesis, Advanced BioHealing, Tengion, Genzyme, HumaCyte and Cytograft Tissue Engineering.

Advisors' Opinion:

• [By Keith Fitz-Gerald]

  In the 4D medical world, Organovo Holdings Inc. (NYSE MKT: ONVO) appears to be off to a good start. They've got a number of bioprinting projects centered around functional human tissue, including a liver product that's planned for 2014. I believe the company will quickly branch into tumor modeling, transplantation, and pharma research.

• [By Roberto Pedone]

  Organovo (ONVO) is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. This stock closed up 8.5% to $5.21 in Thursday's trading session.

  52-Week Range: $1.78-$8.50
  
  Thursday's Volume: 2.88 million
  
  Three-Month Average Volume: 1.78 million

  From a technical perspective, ONVO ripped higher here back above its 50-day moving average of $4.88 with heavy upside volume. This stock has been downtrending badly for the last month, with shares plunging lower from its high of $8.50 to its recent low of $4.43. During that downtrend, shares of ONVO have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of ONVO might be ready to see its downside volatility stop and reverse its downtrend and enter a new uptrend. The probability for that reverse in trend is supported by the high volume on Thursday.

  Traders should now look for long-biased trades in ONVO as long as it's trending above its recent low at $4.33 and then once it sustains a move or close above $5.21 to $5.64 with volume that hits near or above 1.78 shares. If we get that move soon, then ONVO will set up to re-test or possibly take out its next major overhead resistance levels at $6.65 to $7.50.

• [By Jake L'Ecuyer]

  Organovo Holdings (NYSE: ONVO) was also up, gaining 2.54 percent to $9.28. The rise in the shares may be attributed to Thursday's Computerworld Article on 3D printed liver coming in 2014.

• [By James E. Brumley]

  I'll warn you now that if you a fan of or shareholder in Organovo Holdings Inc. (NYSEMKT:ONVO), you're not going to like what you're about to hear. Sorry, but I have to call 'em like I see 'em. And what I see with ONVO is an overbought stock ripe for a big tumble.

Top 10 Medical Stocks To Buy For 2014: DiaMedica Inc (DMA.V)

DiaMedica Inc. (DiaMedica) is a development-stage company. The Company is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. DiaMedica's compound, DM-199, is a recombinant human protein for the treatment of both Type I and Type II diabetes and their complications. DiaMedica is starting a Phase I/II clinical trial for DM-199. DM-199 is a recombinant human protein, which improves glucose control, protects beta cells through the expansion of a population of antigen-specific immunosuppressive cells (Tregs), and proliferates insulin producing beta cells through the activation of certain growth factors. The Company�� DM-204 is a G-protein-coupled receptor agonist (GPCR) monoclonal antibody to treat Type II diabetes and some of the associated complication's. activating a receptor resulted in insulin sensitivity, insulin secretion and vasodilation.

Top 10 Medical Stocks To Buy For 2014: Clovis Oncology Inc (CLVS)

Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.

CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine

CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.

CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor

CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.

The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line treatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.

CO-338-a PARP Inhibitor

CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!

The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.

Advisors' Opinion:

• [By Sean Williams]

  Clovis Oncology (NASDAQ: CLVS  )
  Welcome to fantasyland; population: Clovis shareholders! As my Foolish colleague and health care analyst David Williamson pointed out this week, shareholders enjoyed the best possible perk of biotech ownership Monday based on ASCO data -- a daily double. Clovis shares exploded higher as both its Rucaparib study of solid tumors, and CO-1686 for EGFR-mutant non-small-cell lung cancer, demonstrated strong early-stage results.

Top 10 Medical Stocks To Buy For 2014: Revolutions Medical Corp (RMCP.PK)

Revolutions Medical Corporation (Revolutions Medical), incorporated on August 16, 1996, is principally engaged in the designing, developing and commercializing of retractable vacuum safety needle devices. The Company is engaged in the development of technology which can segment and reference MRI images. The Company also has developed a suite of MRI software tools; RevColor, Rev3D, RevDisplay, and RevScan. MRI (Magnetic Resonance Imaging) is used imaging system that safely creates many different and detailed views of selected portions of the internal anatomy.

The RevVac safety syringe uses vacuum technology to retract the needle into the plunger immediately after use. The syringe cannot be reused once the vacuum is activated. When an MRI is taken, the black and white images are sent to a picture archiving and communication system (PACS), which displays the images for a radiologist to view. By using high speed Internet, these images can be securely sent to the Company�� secure Website, after a secure account is opened. This process is called teleradiology.

The Company competes with Med-Design Corporation, New Medical Technologies, Retractable Technologies, Inc., Unilife, Inc., Specialized Health Products International, BD and Covidien Ltd, Terumo Medical Corp. and B. Braun internationally.

Top 10 Medical Stocks To Buy For 2014: Myriad Genetics Inc (MYGN.O)

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

As of June 30, 2012, the Company h ad launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.

Molecular Diagnostic Tests

The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recu rrence and measure a patient's exposure to drug therapy to! e! nsure optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.

The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.

The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.

< p>Companion Diagnostic Services and Other Revenue

! Throug! h Myriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company's technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company's menu of biomarkers. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.

The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeu tic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.

Top 10 Medical Stocks To Buy For 2014: Telik Inc (TELK)

Telik, Inc. (Telik), incorporated in 1988, is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�� drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells.

Clinical Product Development

TELINTRA is the Company�� lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. It has a mechanism of action and acts by inhibiting GST P1-1, an enzyme that is involved in the control of cellular growth and differentiation. Inhibition of GST P1-1 results in the activation of the signaling molecule Jun kinase, a regulator of the function of blood precursor cells. Preclinical tests show that TELINTRA is capable of causing the death or apoptosis of leukemic or malignant blood cells, while stimulating the growth and development of normal blood precursor cells. TELINTRA has been studied in Myelodysplastic Syndrome (MDS) using two formulations. A liposomal formulation was developed for intravenous administration of TELINTRA and was used in Phase I and Phase II studies in MDS patients. The results from the Phase II intravenous liposomal TELINTRA clinical trials demonstrated that TELINTRA treatment was associated with improvement in all three types of blood cell levels in patients with all types of MDS, including those in intermediate and high-risk groups. An oral dosage formulation (tablet) was subsequently developed and results from a Phase I study with TELINTRA tablets showed clinical activity and the formulation to be well tolerated. In June 2011, the Company initiated a Phase II clinical ! trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. '

The activity and safety profile of tablet formulation allowed the Company to complete a Phase II trial of TELINTRA tablets in MDS. The primary objective of the Phase II TELINTRA tablet study was to determine the efficacy of TELINTRA. A multivariate logistic regression analysis was conducted to identify MDS disease prognostic factors associated with erythroid improvement response rates, including prior MDS treatment, age, gender, the international prognostic scoring system (IPSS), risk, Eastern Cooperative Group performance status, years from MDS diagnosis, MDS World Health Organization subtypes, anemia only versus anemia plus other cytopenias, dose schedule and starting dose. Results from this study show that TELINTRA is the first GSTP1-1 enzyme inhibitor shown to cause clinically reductions in red blood cell transfusions, including transfusion independence in low to intermediate-1 risk MDS patients, as well as improvement in platelet count and white blood cell levels in certain patients. TELINTRA, administered orally twice daily, appeared to be convenient and flexible for chronic treatment administration.

TELCYTA is a small molecule drug product candidate that the Company is developed for the treatment of cancer. TELCYTA binds to GST. TELCYTA has been evaluated in multiple Phase II and Phase III clinical trials, including trials using TELCYTA as monotherapy and in combination regimens in ovarian, non-small cell lung, breast and colorectal cancer. Results from these clinical trials indicate that TELCYTA monotherapy was generally well-tolerated, with mostly mild to moderate side effects, particularly when compared to the side effects and toxicities of standard chemotherapeutic drugs. When TELCYTA was evaluated in combination with standard chemotherapeutic drugs, the tolerability of the combinations was similar to that expected of each! drug alo! ne.

Clinical activity including objective tumor responses and/or disease stabilization was reported in the TELCYTA Phase II trials; however, TELCYTA did not meet its primary endpoints in the Phase III studies. Positive results from a Phase I-IIa multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with non-small cell lung cancer, or NSCLC, were published in a peer reviewed publication. Clinical data demonstrated positive results of TELCYTA in combination with carboplatin and paclitaxel in the treatment of first-line lung cancer followed by TELCYTA maintenance therapy. As of December 31, 2011, the Company had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphoma, and multiple myeloma.

Preclinical Drug Product Development

The Company has a small molecule compound, TLK60404, in preclinical development that inhibits both Aurora kinase and VEGFR kinase. Aurora kinase is a signaling enzyme whose function is required for cancer cell division, while VEGF plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. These lead compounds prevented tumor growth in preclinical models of human colon cancer and human leukemia by inhibiting both Aurora kinase and VEGFR kinase. A development drug product candidate, TLK60404, has been selected.

The Company, using its TRAP technology has discovered TLK60357, a novel, potent small molecule inhibitor of cell division. TLK60357 inhibits the formation of microtubules that are necessary for cancer cell growth leading to persistent G2/M cancer cell cycle block and subsequent cell death. This compound demonstrates potent broad-spectrum anticancer activity against a number of human cancer cells. This compound also displays oral efficacy in multiple, standard preclinical models of cancer. TLK60596, a potent VG! FR kinase! inhibitor, blocks the formation of new blood vessels in tumors. Oral administration of TLK60596 to animal models of human colon cancer reduced tumor growth.

Top 10 Medical Stocks To Buy For 2014: Celgene Corp (CELG.O)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acq uired Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufac turing facility in Boudry, Switzerland.

Comme! rc! ial Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the tre atment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its ! Syste! m ! for Tha! lidomide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed t o Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin -2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a,! leukotri! en! es, and n! itric oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosi s and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical s! tudies ha! ve been! complete! d. An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Top 10 Medical Stocks To Buy For 2014: Quintiles Transnational Holdings Inc (Q)

Quintiles Transnational Holdings Inc. is a provider of biopharmaceutical development services and commercial outsourcing services. The Company operates in two segments: Product Development and Integrated Healthcare Services. The Company�� Product Development segment operates as a contract research organization (CRO) focused primarily on Phase II-IV clinical trials and associated laboratory and analytical activities. The Company�� Integrated Healthcare Services segment is a global commercial pharmaceutical sales and service organizations and Integrated Healthcare Services provides a range of services, including commercial services, such as providing contract pharmaceutical sales forces in geographic markets, as well as healthcare business services for the healthcare sector, such as outcome-based and payer and provider services. In August 2012, it acquired Expression Analysis, Inc.

Product Development

Product Development provides services and that allow biopharmaceutical companies to outsource the clinical development process from first in man trials to post-launch monitoring. The Company�� service offering provides the support and functional necessary at each stage of development, as well as the systems and analytical capabilities. Product Development consists of clinical solutions and services and consulting. Clinical solutions and services provides services necessary to develop biopharmaceutical products, including project management and clinical monitoring functions for conducting multi-site trials (generally Phase II-IV) (core clinical) and clinical trial support services that improve clinical trial decision making and include global laboratories, data management, biostatistical, safety and pharmacovigilance, and early clinical development trials, and strategic planning and design services that improve decisions and performance. Consulting provides strategy and management consulting services based on life science and advanced analytics, as well as regulatory and comp! liance consulting services.

The Company competes with Covance, Inc., Pharmaceutical Product Development, Inc., PAREXEL International Corporation, ICON plc, inVentiv Health, Inc. (inVentive), INC Research and PRA International.

Integrated Healthcare Services

Integrated Healthcare Services provides the healthcare industry with both geographic presence and commercial capabilities. The Company�� commercialization services are designed to accelerate the commercial of biopharmaceutical and other health-related products. Service offerings include commercial services (sales representatives, strategy, marketing communications and other areas related to commercialization), outcome research (drug therapy analysis, real-world research and evidence-based medicine, including research studies to prove a drug�� value) and payer and provider services comparative and cost-effectiveness research capabilities, clinical management analytics, decision support services, medication adherence and health outcome optimization services, and Web-based systems for measuring quality improvement.

The Company competes with inVentiv, PDI, Inc., Publicis Selling Solutions, United Drug plc, EPS Corporation and CMIC HOLDINGS Co., Ltd.

Top 10 Medical Stocks To Buy For 2014: Non-Invasive Monitoring Systems Inc (NIMU.PK)

Non-Invasive Monitoring Systems, Inc. (NIMS), incorporated on July 16, 1980, along with its subsidiaries, is engaged in the research, development, manufacturing and marketing of a line of motorized, non-invasive, whole body, periodic acceleration platforms, which are intended as aids to increase local circulation and temporary relief of minor aches and pains, produce local muscle relaxation and reduce morning stiffness. The Company�� products are derivatives of its original acceleration platform, the AT-101, and are for use in homes, wellness centers and clinics. NIMS is focused on developing and marketing its Exer-Rest line of acceleration therapeutic platforms based upon whole body periodic acceleration (WBPA) technology. The Exer-Rest line of acceleration therapeutic platforms includes the Exer-Rest AT, AT3800 and AT4700 models. In addition, it receives royalty revenue from the sales of non-invasive diagnostic monitoring devices and related software.

W hole Body Periodic Acceleration (WBPA) Therapeutic Devices

The AT-101 is a device that moves a platform repetitively in a head-to-foot motion at a rapid pace. In January 2005, the Company ceased manufacturing the AT-101. The Exer-Rest AT therapeutic vibrator is based upon the design and concept of the AT-101 therapeutic vibrator, but has the dimensions and appearance of a commercial extra long twin bed. The Exer-Rest AT was manufactured by QTM Incorporated (QTM). The wired hand held controller provides digital values of speed, travel and time rather than analog values of speed and arbitrary force values as in the AT-101. the Company discontinued manufacturing of the Exer-Rest AT in July 2009. The Exer-Rest SL and Exer-Rest TL, which were manufactured by Sing Lin Technology Co., Ltd. (Sing Lin), are next generation versions of the Exer-Rest AT and advance the acceleration therapeutic platform technology.

LifeShirt

The LifeShirt is a wea rable physiological computer that incorporates transducers! , ! electrodes and sensors into a sleeveless garment. Pulse oximetry is an optional add-on. These sensors transmit vital and physiological signs to a miniaturized, battery-powered, electronic module which saves the raw waveforms and digital data to the compact flash memory of a Personal Digital Assistant (PDA) attached to the LifeShirt. Users of the LifeShirt can enter symptoms (with intensity), mood and medication information directly into the PDA for integration with the physiologic information collected by the LifeShirt garment. Such data are then transmitted from the flash memory to a data collection center that transforms the data into minute-by-minute median trends of over 30 physical and emotional signs of health and disease. In addition, the monitored patient can enter symptoms with intensity, mood, and medication directly into the PDA for integration with the physiologic information collected with the LifeShirt garment. As of July 31, 2009, LifeShirt was not marketed. T he LifeShirt was sold by VivoMetrics, but has not been marketed since VivoMetrics ceased operations in July 2009.

The Company competes with Power Plate of North America, Vibraflex and CERAGEM International, Inc.

5 Best Casino Stocks For 2014

Some fast-growing companies trade at valuations that just don't make sense. Though many of these stocks probably present worse probabilities of success than a casino, a rare few are well deserving of their unthinkable premiums. What separates them from the rest? Two things: excellent economics and massive market opportunity. Case in point: Facebook (NASDAQ: FB  ) and Amazon.com (NASDAQ: AMZN  ) -- two top stocks for investors looking for growth.

Facebook
Facebook's business model inherently drives demand through the network effect. With each additional user, the platform becomes more useful -- both for users and advertisers. Nowhere is Facebook's network effect more evident than in its continually improving engagement rate, or the percentage of monthly active users, or MAUs, who use Facebook on a daily basis.

In the company's first-quarter results, 60% of its 1.1 billion MAUs used Facebook on a daily basis versus 58% of its 900 million users in 2012. In the U.S. and Canada, growing engagement was even more evident, with 92% of users accessing Facebook on a daily basis compared with 70% last year.

5 Best Casino Stocks For 2014: Penn National Gaming Inc.(PENN)

Penn National Gaming, Inc. and its subsidiaries own and manage gaming and pari-mutuel properties in the United States. It operates approximately 27,000 gaming machines; 500 table games; and 2,000 hotel rooms in 23 facilities in 16 jurisdictions, including Colorado, Florida, Illinois, Indiana, Iowa, Louisiana, Maine, Maryland, Mississippi, Missouri, New Jersey, New Mexico, Ohio, Pennsylvania, West Virginia, and Ontario. The company was formerly known as PNRC Corp. and changed its name to Penn National Gaming, Inc. in 1994. Penn National Gaming, Inc. was founded in 1982 and is based in Wyomissing, Pennsylvania.

Advisors' Opinion:

• [By Roberto Pedone]

   

  Penn National Gaming (PENN) is a diversified, multi-jurisdictional owner and manager of gaming and pari-mutuel properties. This stock closed up 1.4% at $56.13 in Monday's trading session.

   

  Monday's Volume: 1.11 million
  
  Three-Month Average Volume: 824,334
  
  Volume % Change: 73%

   

   

  From a technical perspective, PENN jumped modestly higher here right above some near-term support at $54.71 with above-average volume. This move is quickly pushing shares of PENN within range of triggering a breakout trade. That trade will hit if PENN manages to take out some near-term overhead resistance at $57.44 to some past resistance at $58 with high volume.

   

  Traders should now look for long-biased trades in PENN as long as it's trending above Monday's low $55.65 or above more support at $54.71 and then once it sustains a move or close above those breakout levels with volume that this near or above 824,334 shares. If that breakout hits soon, then PENN will set up to re-test or possibly take out its 52-week high at $59.93. Any high-volume move above $59.93 will then give PENN a chance to hit $65.

   

• [By Paul Ausick]

  Stocks on the Move: BlackBerry Ltd. (NASDAQ: BBRY) is down 16.4% at $6.50 after announcing that no buyout bid will be forthcoming. Penn National Gaming Inc. (NASDAQ: PENN) is down 76.7% at $13.75 after spinning-off its real-estate holdings into a REIT. Suntech Power Holdings Co. Ltd. (NYSE: STP) is up 15.5% at $1.53 following the acquisition of its major operations in Wuxi.

• [By Paul Ausick]

  Penn National Gaming Inc. (NASDAQ: PENN) completed on Monday the spin-off of its real-estate holdings into a new REIT, Gaming and Leisure Properties Inc. (G&LP) (NASDAQ: GLPI). The spin-off was first announced a year ago. Shares in GLPI are trading at around $46.51 after opening at $45.76 this morning.

5 Best Casino Stocks For 2014: Caesars Entertainment Corp (CZR)

Caesars Entertainment Corporation, incorporated on November 2, 1989, is a diversified casino-entertainment provider. The Company�� business is primarily conducted through a wholly owned subsidiary, Caesars Entertainment Operating Company, Inc. (CEOC), although certain material properties are not owned by CEOC. As of December 31, 2012, it owned, operated, or managed, through various subsidiaries, 52 casinos in 13 United States states and seven countries. The majority of these casinos operate in the United States, primarily under the Caesars, Harrah��, and Horseshoe brand names, and in England. In November 2012, the Company sold its Harrah's St. Louis casino to Penn National Gaming, Inc. In December 2012, the Company purchased all of the net assets of Buffalo Studios, LLC, a social and mobile games developer and owner of Bingo Blitz.

The Company�� casino entertainment facilities include 33 land-based casinos, 11 riverboat or dockside casinos, three managed casinos on Indian lands in the United States, one managed casino in Cleveland, Ohio, one managed casino in Canada, one casino combined with a greyhound racetrack, one casino combined with a thoroughbred racetrack, and one casino combined with a harness racetrack. The Company�� land-based casinos include nine in England, two in Egypt, one in Scotland, one in South Africa and one in Uruguay. As of December 31, 2012, its facilities had an aggregate of approximately three million square feet of gaming space and approximately 43,000 hotel rooms. In southern Nevada, Caesars Palace, Harrah�� Las Vegas, Rio All-Suite Hotel & Casino, Bally�� Las Vegas, Flamingo Las Vegas, Paris Las Vegas, Planet Hollywood Resort and Casino, The Quad Resort & Casino (formerly the Imperial Palace Hotel and Casino), Bill�� Gamblin��Hall & Saloon, and Hot Spot Oasis are located in Las Vegas and draw customers from throughout the United States. Harrah�� Laughlin is located near both the Arizona and California borders and draws customers primarily from! the southern California and Phoenix metropolitan areas and, to a lesser extent, from throughout the United States through charter aircraft. In northern Nevada, Harrah�� Lake Tahoe and Harveys Resort & Casino are located near Lake Tahoe and Harrah�� Reno is located in downtown Reno. These facilities draw customers primarily from northern California, the Pacific Northwest, and Canada.

The Company�� Atlantic City casinos, Harrah�� Resort Atlantic City, Showboat Atlantic City, Caesars Atlantic City, and Bally�� Atlantic City, draw customers primarily from the Philadelphia metropolitan area, New York, and New Jersey. Harrah�� Philadelphia (formerly Harrah's Chester) is a combination harness racetrack and casino located approximately six miles south of Philadelphia International Airport and draws customers primarily from the Philadelphia metropolitan area and Delaware. The Company�� Chicagoland dockside casinos, Harrah�� Joliet in Joliet, Illinois, and Horseshoe Hammond in Hammond, Indiana, draw customers primarily from the greater Chicago metropolitan area. In southern Indiana, it owns Horseshoe Southern Indiana, a dockside casino complex located in Elizabeth, Indiana, which draws customers primarily from northern Kentucky, including the Louisville metropolitan area, and southern Indiana, including Indianapolis. In Louisiana, the Company owns Harrah�� New Orleans, a land-based casino located in downtown New Orleans, which attracts customers primarily from the New Orleans metropolitan area. In northwest Louisiana, Horseshoe Bossier City, a dockside casino, and Harrah�� Louisiana Downs, a thoroughbred racetrack with slot machines, both located in Bossier City, cater to customers in northwestern Louisiana.

The Company owns the Grand Casino Biloxi, located in Biloxi, Mississippi, which caters to customers in southern Mississippi, southern Alabama, and northern Florida. Harrah�� North Kansas City dockside casino draws customers from the Kansas City metropolitan ar! ea. Harra! h�� Metropolis is a dockside casino located in Metropolis, Illinois, on the Ohio River, drawing customers from southern Illinois, western Kentucky, and central Tennessee. Horseshoe Tunica, Harrah�� Tunica, and Tunica Roadhouse Hotel & Casino, dockside casino complexes located in Tunica, Mississippi, are approximately 30 miles from Memphis, Tennessee and draw customers primarily from the Memphis area and, to a lesser extent, from throughout the United States through charter aircraft. Horseshoe Casino and Bluffs Run Greyhound Park, a land-based casino and pari-mutuel facility, and Harrah�� Council Bluffs Casino & Hotel, a dockside casino facility, are located in Council Bluffs, Iowa, across the Missouri River from Omaha, Nebraska. At Horseshoe Casino and Bluffs Run Greyhound Park, the Company owns the assets other than gaming equipment, and leases these assets to the Iowa West Racing Association (IWRA), a nonprofit corporation, and it manages the facility for the IWRA under a management agreement expiring in October 2024. The license to operate Harrah�� Council Bluffs Casino & Hotel is held jointly with IWRA, the qualified sponsoring organization.

The Conrad Resort & Casino located in Punta Del Este, Uruguay (the Conrad), draws customers primarily from Argentina and Uruguay. In November 2012, the Company announced that it had entered into a definitive agreement with Enjoy S.A. (Enjoy) to form a strategic relationship in Latin America. Under the terms of the agreement, Enjoy will acquire 45% of Baluma S.A., its subsidiary, which owns and operates the Conrad, and the Company will become a 10% shareholder in Enjoy upon consummation of the agreement. Upon the closing of the transaction, which is subject to certain conditions, including the receipt of all regulatory and governmental approvals, Enjoy will assume primary responsibility for management of the Conrad. Enjoy will have the option to acquire the remaining stake in Baluma S.A. between years three and five following closing. The cl! osing of ! the transaction remains subject to a number of conditions, including regulatory and governmental approvals in both Uruguay and Chile.

The Company owns four casinos in London: the Sportsman, the Golden Nugget, The Playboy Club London, and The Casino at the Empire. Its casinos in London draw customers primarily from the London metropolitan area, as well as international visitors. The Company also owns Alea Nottingham, Alea Glasgow, Alea Leeds, Manchester 235, Rendezvous Brighton, and Rendezvous Southend-on-Sea in the provinces of the United Kingdom, which primarily draw customers from their local areas. Pursuant to a concession agreement, it also operates two casinos in Cairo, Egypt, The London Club Cairo (which is located at the Ramses Hilton) and Caesars Cairo (which is located at the Four Seasons Cairo), which draw customers primarily from other countries in the Middle East. Emerald Safari, located in the province of Gauteng in South Africa, draws customers primarily from South Africa. It owsn and operates Bluegrass Downs, a harness racetrack located in Paducah, Kentucky.

The Company owns three casinos for Indian tribes: Harrah�� Phoenix Ak-Chin, located near Phoenix, Arizona, Harrah�� Cherokee Casino and Hotel, and Harrah�� Rincon Casino and Resort, located near San Diego, California. The Company manages Caesars Windsor, located in Windsor, Ontario, which draws customers primarily from the Detroit metropolitan area, Horseshoe Cleveland casino in Ohio, which it manages for Rock Ohio Caesars LLC (ROC), a venture with Rock Ohio Ventures, LLC (Rock Gaming), in which it has a 20% equity interest, and the Horseshoe Cincinnati casino in Ohio for ROC for a fee under a management agreement that will expire in March 2033. It also has a minority interest in Sterling Suffolk Racecourse, LLC (Suffolk Downs), which owns a horse-racing track in Boston, Massachusetts, and the right to manage a future gaming facility. The Company also owns ans operates a golf course on 175 acres of prime real! estate t! hrough a land concession on the Cotai strip in Macau.

Advisors' Opinion:

• [By Sean Williams]

  Always bet on red
  The knock against the casino sector is twofold. First, the capital investment needed to build resorts and casinos is phenomenally high, which often puts casinos deeply into debt. If the cash flow is there and the equity level is high, this isn't a problem. In other cases it's downright scary. Take Caesars Entertainment (NASDAQ: CZR  ) , for example, which has roughly $19.5 billion in net debt and could have trouble keeping up with its interest payments if it takes on any additional debt.

Top Clean Energy Stocks To Invest In 2014: (XTRN)

Las Vegas Railway Express Inc. focuses to re-establish a conventional passenger train service between the Las Vegas and Los Angeles metropolitan areas. It plans to establish a ?Vegas-style? passenger train service. The company is based in Las Vegas, Nevada.

5 Best Casino Stocks For 2014: Nevada Gold & Casinos Inc (UWN)

Nevada Gold & Casinos, Inc., incorporated on April 7, 1977, is primarily a gaming company involved in financing, developing, owning and operating gaming projects. Through the Company's wholly owned subsidiary, Gold Mountain Development, LLC, the Company owns approximately 268 acres of undeveloped land in the vicinity of Black Hawk, Colorado. On January 27, 2012, through the Company's wholly owned subsidiary, NG South Dakota, LLC, the Company acquired A.G. Trucano, Son & Grandsons, Inc. (South Dakota Gol). On July 18, 2011, through the Company's wholly owned subsidiary, NG Washington III, LLC, the Company acquired Red Dragon mini-casino in Mountlake Terrace, Washington (Washington III). On May 25, 2012, the Company sold all of the assets, including rights in the Colorado Grande name and gaming-related liabilities, of the Colorado Grande Casino to G Investments, LLC (GI).

Commercial Gaming Projects

The Company owns and operates 10 gaming facilities in Washington, and a slot machine route operation in South Dakota. These properties are wholly owned and operated by the Company: the Crazy Moose Casinos in Pasco and Mountlake Terrace, Washington, the Coyote Bob�� Casino in Kennewick, Washington, the Silver Dollar Casinos in SeaTac, Bothell and Renton, Washington, the Club Hollywood Casino in Shoreline, Washington, the Royal Casino in Everett, Washington, the Golden Nugget Casino in Tukwila, Washington, and the Red Dragon Casino in Mountlake Terrace, Washington (Washington Gold), and the South Dakota Gold slot route operation in Deadwood, South Dakota.

Commercial Casino Projects

The Company own two mini-casinos operating in Mountlake Terrace. The Red Dragon mini-casino, located in western Washington State, has a total of 15 table games, including Player Banked Poker, Baccarat, and other banked table games. The mini-casino is located within 14 miles of downtown Seattle. South Dakota Gold is a slot machine route that operates over 900 slots at approximate! ly 20 locations in Deadwood, South Dakota, which represent about 24% of the total number of slot machines in that market. Deadwood is a town of 1,300 residents located in the Black Hills, South Dakota, in the southwest corner of the state.

5 Best Casino Stocks For 2014: Pinnacle Entertainment Inc.(PNK)

Pinnacle Entertainment, Inc. owns, develops, and operates casinos, and related hospitality and entertainment facilities in the United States. It operates casinos, such as L'Auberge du Lac in Lake Charles, Louisiana; River City Casino and Lumiere Place in St. Louis, Missouri; Boomtown New Orleans in New Orleans, Louisiana; Belterra Casino Resort in Vevay, Indiana; Boomtown Bossier City in Bossier City, Louisiana; and Boomtown Reno in Reno, Nevada. The company also operates River Downs racetrack in southeast Cincinnati, Ohio. As of May 26, 2011, it operated seven casinos and one racetrack. The company was formerly known as Hollywood Park, Inc. and changed its name to Pinnacle Entertainment, Inc. in February 2000. Pinnacle Entertainment, Inc. was founded in 1935 and is based in Las Vegas, Nevada.

Advisors' Opinion:

• [By Sean Williams]

  Time to make the switch
  If I could name a sector that I'd certainly tread lightly around considering that consumers are tightening their wallets, it would be the casino sector. Casino companies rely on loose wallets and vacations to drive profits. This is why I feel it could be the time to say goodbye to casino and race track operator Pinnacle Entertainment (NYSE: PNK  ) near its 52-week high.

• [By Dan Radovsky]

  Pinnacle Entertainment (NYSE: PNK  ) has reached an agreement in principle with the Bureau of Competition of the Federal Trade Commission that would allow the company to complete its proposed acquisition of Ameristar Casinos (NASDAQ: ASCA  ) , Pinnacle announced today.

• [By Travis Hoium]

  What: Shares of Ameristar Casinos (NASDAQ: ASCA  ) and Pinnacle Entertainment (NYSE: PNK  ) fell as much as 11% today after the government brought into question the merger of the two companies.

• [By Ben Levisohn]

  Pinnacle Entertainment (PNK) has gained 56% this year; Las Vegas Sands (LVS) has climbed 38%. And Deutsche Bank has nice things to say about both today.

  Bloomberg

  First Pinnacle. Deutsche Bank’s Carlo Santarelli ponders the stock’s big move and comes away still seeing value in its shares. He writes:

  When we upgraded PNK in April, our thesis centered on the FCF strength of the combined entities [Pinnacle completed its acquisition of Ameristar Casinos on Aug. 14], a handful of favorable catalysts, easing regional gaming comps, & an inexpensive relative valuation. Given the shares’ sizeable move since then, we believe it is worth revisiting the investment case. Post the announcement of several asset sales and the closing of the transaction, we are adjusting our estimates, raising our PT to $30 from $24, and maintaining our bullish view at current levels given what we still believe to be an attractive free cash flow valuation, meaningful potential synergy realization beyond the $40 mm of announced benefits, and a free option on a lagging regional recovery.

  Santarelli also revisited Las Vegas Sands and there too, he likes what he sees. He writes:

  With…LVS at [a share price level] that have been challenging to break from over the last year plus, we believe this time is different and hence we see continued upward momentum…In the case of LVS, we see; 1) meaningful mass market strength continuing through year end, setting the stage for upward company and market estimate revisions for 2014, 2) continued cash flow appreciation and capital returns serving as downside protection and positive catalysts, and 3) continued shared gains, largely driven by table optimization and mass market strength, driving both estimates and sentiment.

  He also likes Wynn Resorts (WYNN), despite its 34% gain.�Santarelli writes:

  As for WYNN, we believe near-term estimates continue to take a back seat to capital return

Top Undervalued Stocks To Buy For 2014

Small cap BioScrip Inc (NASDAQ: BIOS) is a specialized health care services stock that���seeking to roll-up the heavily fragmented�home infusion care market���meaning its worth taking a closer look at the stock and its performance against healthcare ETFs like the iShares Dow Jones US Health Care ETF (NYSEARCA: IHF) or the Health Care SPDR ETF (NYSEARCA: XLV). However,�BioScrip has taken a beating and I should note that we have recently added shares to our SmallCap Network Elite Opportunity (SCN EO) portfolio�because we believe the company is on the verge of turning a profit and is potentially undervalued.

What is BioScrip Inc?

Small cap BioScrip provides comprehensive infusion and home care solutions. More specifically, BioScrip provides access to infusible medications and management solutions to optimize outcomes for chronic and other complex healthcare conditions.�BioScrip also offers complete Pharmacy Benefit Management programs that include customized benefit plan design, pharmacy network management and sophisticated reporting capabilities plus the company�has 33 retail locations in 25 major metropolitan markets across the US providing nationwide capabilities.

Top Undervalued Stocks To Buy For 2014: Dollar Tree Inc.(DLTR)

Dollar Tree, Inc. operates discount variety stores in the United States and Canada. Its stores offer merchandise primarily at the fixed price of $1.00. The company operates its stores under the names of Dollar Tree, Deal$, Dollar Tree Deal$, Dollar Giant, and Dollar Bills. Its stores offer consumable merchandise, including candy and food, and health and beauty care, as well as household consumables, such as paper, plastics, household chemicals, in select stores, and frozen and refrigerated food; variety merchandise, which includes toys, durable housewares, gifts, party goods, greeting cards, softlines, and other items; and seasonal goods, such as Easter, Halloween, and Christmas merchandise. As of April 30, 2011, it operated 4,089 stores in 48 states and the District of Columbia, as well as 88 stores in Canada. The company was founded in 1986 and is based in Chesapeake, Virginia.

Advisors' Opinion:

• [By Dan Moskowitz]

  The shiniest dollar
  Many investors and analysts like to debate which dollar store offers the best investment opportunity. The truth is that Dollar General, Dollar Tree Stores (NASDAQ: DLTR  ) , and Family Dollar Stores (NYSE: FDO  ) are all likely to be quality long-term investments.

• [By Ethan Roberts]

  Shares of Dollar Tree (DLTR) were substantially lower this morning after the company reported third-quarter earnings. Dollar Tree earnings tallied 59 cents per diluted share of DLTR stock, which missed analyst estimates by two pennies.

• [By Jon C. Ogg]

  Deutsche Bank is making a change in its coverage of dollar store themes on Monday: Dollar Tree Inc. (NASDAQ: DLTR) was raised to Buy from Hold and Family Dollar Stores Inc. (NYSE: FDO)�was downgraded to Hold from Buy, but the price target was raised to $74 from $70.

• [By Demitrios Kalogeropoulos]

  Costly market share gains
  The problem is that Family Dollar has had to pay up for its increasing market share and sales levels. The company's gross profit margin fell by more than a full percentage point, to 34.7% last quarter. In contrast, Dollar Tree (NASDAQ: DLTR  ) booked an expansion of profits, to 35.2%, continuing a trend that's seen it pull away from Family Dollar.

Top Undervalued Stocks To Buy For 2014: Caterpillar Inc.(CAT)

Caterpillar Inc. manufactures and sells construction and mining equipment, diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives worldwide. It operates through three lines of businesses: Machinery, Engines, and Financial Products. The Machinery business offers construction, mining, and forestry machinery, including track and wheel tractors, track and wheel loaders, pipelayers, motor graders, wheel tractor-scrapers, track and wheel excavators, backhoe loaders, log skidders, log loaders, off-highway trucks, articulated trucks, paving products, skid steer loaders, underground mining equipment, tunnel boring equipment, and related parts. It also manufactures diesel-electric locomotives; and manufactures and services rail-related products and logistics services for other companies. The Engines business provides diesel, heavy fuel, and natural gas reciprocating engines for Caterpillar machinery, electric power generation systems, marine, petrol eum, construction, industrial, agricultural, and other applications. It offers industrial turbines and turbine-related services for oil and gas, and power generation applications. This business also remanufactures Caterpillar engines, machines, and engine components; and offers remanufacturing services for other companies. The Financial Products business provides retail and wholesale financing alternatives for Caterpillar machinery and engines, solar gas turbines, and other equipment and marine vessels, as well as offers loans and various forms of insurance to customers and dealers. It also offers financing for vehicles, power generation facilities, and marine vessels. The company markets its products directly, as well as through its distribution centers, dealers, and distributors. It was formerly known as Caterpillar Tractor Co. and changed its name to Caterpillar Inc. in 1986. Caterpillar Inc. was founded in 1925 and is headquartered in Peoria, Illinois.

Advisors' Opinion:

• [By Rich Duprey]

  China's manufacturing sector is contracting at an alarming rate, and Caterpillar's (NYSE: CAT  ) stock may not be able to surmount the obstacles the collapse is throwing in its path.

• [By Dan Carroll]

  Another manufacturer on the Dow is vaulting higher after Alcoa's earnings hit: Caterpillar (NYSE: CAT  ) shares have gained 3.2% on the day to lead the index higher. Caterpillar has suffered many of the same problems as Alcoa, with waning demand -- particularly from China and Europe, which are experiencing an economic slowdown and a brutal recession, respectively -- hurting the company's near-term outlook. Caterpillar's expectations of firm Chinese growth look lackluster at best now.

Top 5 Tech Stocks To Invest In Right Now: Tupperware Corporation(TUP)

Tupperware Brands Corporation operates as a direct seller of various products across a range of brands and categories through an independent sales force. The company engages in the manufacture and sale of kitchen and home products, and beauty and personal care products. It offers preparation, storage, and serving solutions for the kitchen and home, as well as kitchen cookware and tools, children?s educational toys, microwave products, and gifts under the Tupperware brand name primarily in Europe, Africa, the Middle East, the Asia Pacific, and North America. The company provides beauty and personal care products, which include skin care products, cosmetics, bath and body care, toiletries, fragrances, nutritional products, apparel, and related products principally in Mexico, South Africa, the Philippines, Australia, and Uruguay. It offers beauty and personal care products under the Armand Dupree, Avroy Shlain, BeautiControl, Fuller, NaturCare, Nutrimetics, Nuvo, and Swissgar de brand names. The company sells its Tupperware products directly to distributors, directors, managers, and dealers; and beauty products primarily through consultants and directors. As of December 26, 2009, the Tupperware distribution system had approximately 1,800 distributors, 61,300 managers, and 1.3 million dealers; and the sales force representing the Beauty businesses approximately 1.1 million. The company was formerly known as Tupperware Corporation and changed its name to Tupperware Brands Corporation in December 2005. The company was founded in 1996 and is headquartered in Orlando, Florida.

Advisors' Opinion:

• [By Monica Gerson]

  Tupperware Brands (NYSE: TUP) is expected to report its Q3 earnings at $1.03 per share on revenue of $623.34 million.

  Varian Medical Systems (NYSE: VAR) is projected to post its Q4 earnings at $1.12 per share on revenue of $779.02 million.

• [By Oliver Pursche]

  European large-cap pharmaceuticals like Novartis (NVS) �and Bristol Meyers Squibb (BMY) �count amongst some of our favorite stocks right now, as do U.S. multinationals that are growing revenue and margins in Asia ��Tupperware (TUP) �is a shining example. Stay away from utilities and energy stocks, as they are likely to be the laggards over the next year.

• [By Ben Levisohn]

  Shares of Herbalife have gained 0.9% to $79.51 this morning in pre-open trading. Its shares have gained 139% this year, a nice gain, but lagging Nu Skin Enterprises 271% rise. Avon Products�(AVP), another multi-level marketer, has gained 21% so far this year, while Tupperware Brands�(TUP) has risen 49%.

Top Undervalued Stocks To Buy For 2014: Schlumberger N.V.(SLB)

Schlumberger Limited, together with its subsidiaries, supplies technology, integrated project management, and information solutions to the oil and gas exploration and production industries worldwide. The company?s Oilfield Services segment provides exploration and production services; wireline technology that offers open-hole and cased-hole services; supplies engineering support, directional-drilling, measurement-while-drilling, and logging-while-drilling services; and testing services. This segment also offers well services; supplies well completion services and equipment; artificial lift; data and consulting services; geo services; and information solutions, such as consulting, software, information management system, and IT infrastructure services that support oil and gas industry. Its WesternGeco segment provides reservoir imaging, monitoring, and development services; and operates data processing centers and multiclient seismic library. This segment also offers variou s services include 3D and time-lapse (4D) seismic surveys to multi-component surveys for delineating prospects and reservoir management. The company?s M-I SWACO segment supplies drilling fluid systems to improve drilling performance; fluid systems and specialty tools to optimize wellbore productivity; production technology solutions to maximize production rates; and environmental solutions that manages waste volumes generated in drilling and production operations. Its Smith Oilfield segment designs, manufactures, and markets drill bits and borehole enlargement tools; and supplies drilling tools and services, tubular, completion services, and other related downhole solutions. The company?s Distribution segment markets pipes, valves, and fittings, as well as mill, safety, and other maintenance products. This segment also provides warehouse management, vendor integration, and inventory management services. Schlumberger Limited was founded in 1927 and is based in Houston, Texas.

Advisors' Opinion:

• [By Rich Duprey]

  Oil and gas industry services providers Cameron International (NYSE: CAM  ) and Schlumberger (NYSE: SLB  ) announced today that their�OneSubsea joint venture had received all required regulatory approvals and that they'll close on the JV on�June 30.

• [By Michael Fitzsimmons]

  So what is GE to do? The O&G segment is a very fast growing and nicely profitable business that is synergistic with the rest of GE's industrial operations. Yet it is such a small part of the company, its valuation is being diluted by GE's other businesses. A spin-off would surely unlock value. That said, a spun-off O&G company would be a relatively small player compared to a companies like Schlumberger (SLB), with $42 billion in 2012 revenue and a P/E=19.5, and even Haliburton (HAL), with $24.8 billion in 2012 revenue and a P/E=23.6. But both these companies trade at a premium valuation to GE (P/E=17.8) despite GE's higher dividend yield (3.1%).

• [By Dan Caplinger]

  Halliburton's share-price gains began early in the quarter after the company reported its first-quarter results. Although the company took a massive $637 million charge related to the 2010 Gulf disaster, Halliburton managed to hold its own on the domestic front in a weak environment. Internationally, the company cleaned up, with sales rising 21% and at more than twice that rate in the Eastern Hemisphere. But, perhaps most importantly, Halliburton looked favorably on the near-future for domestic drilling, noting gains in margins, and some pricing power expected to enhance profitability from rising well production. That's consistent with the results we saw from Schlumberger (NYSE: SLB  ) this morning, as the industry leader beat earnings expectations with a nearly 50% jump in its net profits, coming largely from overseas activity, but also posting a 2% revenue increase in North America.

Top Stocks To Invest In 2014

In the following video, Fool.com analyst Blake Bos discusses whether to buy or sell GameStop (NYSE: GME  ) . He says the company is ready for another console life cycle to begin and help boost the sale of its high-margin used games and other business lines. He also argues that the gaming community isn't completely ready for online-only consoles, which works in the company's favor, but that it should begin preparing for the inevitable shift toward exclusively digital downloads only. For now, he says, the company is incredibly cheap in terms of free cash flow, and P/E ratio, plus it has no debt, so it appears that any fears that the business will soon run into financial troubles are overblown.

Xbox maker struggles
It's been a frustrating path for Microsoft investors, who've watched the company fail to capitalize on the incredible growth in mobile over the past decade. However, with the release of its own tablet, along with the widely anticipated Windows 8 operating system, the company is looking to make a splash in this booming market. In this brand-new premium report on Microsoft, our analyst explains that while the opportunity is huge, the challenges are many. He's also providing regular updates as key events occur, so make sure to claim a copy of this report now by clicking here.

Top Stocks To Invest In 2014: Energy Fuels Inc Com Npv (EFR.TO)

Energy Fuels Inc. engages in the exploration, development, and production of uranium and vanadium properties in the United States. The company�s principal properties include the White Mesa mill located near Blanding, Utah; the Arizona Strip uranium properties located in north central Arizona; the Colorado Plateau uranium/vanadium properties located to the southwestern Colorado and southeastern Utah border; the Daneros mine situated in the White Canyon district in southeastern Utah; the Henry Mountains Complex uranium properties in south central Utah; the Sheep Mountain project located in Fremont County, Wyoming; and the Pi帽on Ridge uranium and vanadium mill project located near the town of Bedrock. The company was formerly known as Volcanic Metals Exploration Inc. and changed its name to Energy Fuels Inc. in May 2006. Energy Fuels Inc. was incorporated in 1987 and is headquartered in Toronto, Canada.

Top Stocks To Invest In 2014: Capital City Bank Group(CCBG)

Capital City Bank Group, Inc. operates as the bank holding company for Capital City Bank that provides commercial and retail banking products and services. Its deposit products include negotiable order of withdrawal accounts, money market accounts, checking and savings accounts, and time deposits. The company offers financing for commercial business properties, equipment, inventories, and accounts receivable, as well as commercial leasing and letters of credit; commercial and residential real estate lending; retail credit products, including personal loans, automobile loans, boat/recreational vehicle loans, home equity loans, and credit card programs; and tax-exempt loans, lines of credit, and term loans. It also provides treasury management services, merchant credit card transaction processing services, automated teller machines (ATMs), debit/credit cards, night deposit services, safe deposit facilities, PC/Internet banking, and mobile banking services. In addition, the c ompany offers asset management, trust, mortgage banking, merchant services, and data processing services, as well as securities brokerage services, including U.S. government bonds, tax-free municipal bonds, stocks, mutual funds, unit investment trusts, annuities, life insurance, and long-term health care. It serves individuals, corporations, and other business clients, including commercial developers and investors, residential builders and developers, community developers, state and local governments, public schools and colleges, charities, and membership and not-for-profit associations. As of January 27, 2012, the company operated 70 banking offices and 79 ATMs in Florida, Georgia, and Alabama. Capital City Bank Group, Inc. was founded in 1895 and is headquartered in Tallahassee, Florida.

Advisors' Opinion:

• [By Dividends4Life]

  Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description:
  
  1. Avg. High Yield Price
  2. 20-Year DCF Price
  3. Avg. P/E Price
  4. Graham Number
  
  CTBI is trading at a premium to all four valuations above. The stock is trading at a 53.5% premium to its calculated fair value of $29.43. CTBI did not earn any Stars in this section.
  
  Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description:
  
  1. Free Cash Flow Payout
  2. Debt To Total Capital
  3. Key Metrics
  4. Dividend Growth Rate
  5. Years of Div. Growth
  6. Rolling 4-yr Div. > 15%
  
  CTBI earned one Star in this section for 1.) above. A Star was earned since the Free Cash Flow payout ratio was less than 60% and there were no negative Free Cash Flows over the last 10 years. The company has paid a cash dividend to shareholders every year since 1988 and has increased its dividend payments for 33 consecutive years.
  
  Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description:
  
  1. NPV MMA Diff.
  2. Years to > MMA
  
  The negative NPV MMA Diff. means that on a NPV basis the dividend earnings from an investment in CTBI would be less than a similar amount invested in MMA earning a 20-year average rate of 3.41%. If CTBI grows its dividend at 1.5% per year, it will never equal a MMA yielding an estimated 20-year average rate of 3.41%.
  
  Memberships and Peers: CTBI is, a member of the Broad Dividend Achieve

Hot Tech Stocks To Buy Right Now: Apartment Investment and Management Co (AIV)

Apartment Investment and Management Company (Aimco), incorporated on January 10, 1994, is a self-administered and self-managed real estate investment trust (REIT). The Company is engaged in the ownership and operation of a portfolio of apartment properties. Through its wholly owned subsidiaries, AIMCO-GP, Inc. and AIMCO-LP Trust, it owns majority interests in AIMCO Properties, L.P., which it refers to as the Aimco Operating Partnership. The Company conducts substantially all of its business and owns substantially all of its assets through the Aimco Operating Partnership. As of December 31, 2011, Aimco�� portfolio of owned and/or managed properties consisted of 518 properties with 93,694 apartment units.

During the year ended December 31, 2011, the Company acquired limited partnership interests in 12 real estate partnerships that owned 15 properties and in which its affiliates served as general partner. During 2011, it acquired a vacant, 126-unit property located in Marin County, north of San Francisco, California. During 2011, it acquired 50% interest in entities that owned four contiguous properties with 142 units located in La Jolla, California. During 2011, it sold 67 consolidated properties. During 2011, the Company owned general and limited partner interests in real estate partnerships that owned approximately 123 properties.

Property Operations

The Company�� owned real estate portfolio consists of two business components: conventional and affordable property operations. Its conventional property operations consist of market-rate apartments with rents paid by the resident and included 198 properties with 62,834 units in which it held an average interest of 93% as of December 31, 2011. The Company�� affordable property operations consist of apartments with rents that are generally paid, in whole or part, by a government agency and consisted of 172 properties with 20,612 units in which it held an average interest of 59% as of December 31, 2011. The Compa! ny�� property operations are organized into two geographic areas, the West and East.

Portfolio Management

As of December 31, 2011, the Company�� affordable portfolio included 172 properties with 20,612 units. As of December 31, 2011, its conventional portfolio included 198 properties with 62,834 units in 33 markets.

Advisors' Opinion:

• [By Sean Williams]

  Apartment Investment & Management Co. (NYSE: AIV  )
  When long-term lending rates began rising dramatically just a few weeks ago, anything related to the housing sector dove, including apartment rental community operator Apartment Investment & Management, better known as AIMCO. Investors who sold may have made a big mistake, as rental communities look to be stronger than ever as the housing sector gets caught in a nasty catch-22.

Top Stocks To Invest In 2014: Olympia Financial Group Inc (OLY.V)

Olympia Financial Group Inc., through its subsidiary, Olympia Trust Company, operates as a non-deposit taking trust company in Canada. It acts as a trustee and manages self-administered registered plans; acts as a registrar and transfer agent for public companies; administers employee stock purchase plans for corporations; and provides foreign currency exchange services and other trustee services. The company offers corporate and shareholder services, including security holder recordkeeping and transfer services, direct registration system, generic certificate inventory program, security holder meeting and mailing services, Escrow agent services, security holder communication services, initial public offerings, and online issuer reports. Its corporate and shareholder services also comprise disbursing agent for dividend, distribution and interest payments, plan agent for dividend/distribution reinvestment plans and optional cash payment plans, administration of employee inc entive plans, administration of stock option liquidation plan, depository for corporate reorganizations and takeover bids, shareholder rights protection plans, corporate trustee services, and SEDAR filing services. In addition, the company provides self-administered registered plans, which primarily include registered retirement savings plans, tax free savings accounts, and education savings plans; and corporate and personal foreign currency exchange services, such as buy/sell transactions, forward contracts, and market orders. Further, it offers self-insured private health services plans. The company was incorporated in 1994 and is headquartered in Calgary, Canada.

Top Stocks To Invest In 2014: Volkswagen Ag(VKW.L)

Volkswagen Aktiengesellschaft, together with its subsidiaries, engages in the manufacture and sale of automobiles worldwide. The company operates in two divisions, Automotive and Financial Services. The Automotive division engages in the development of vehicles and engines; production and sale of passenger cars, commercial vehicles, trucks, and buses; manufacture of large-bore diesel engines for marine and stationary applications, turbochargers, turbomachinery, compressors, and chemical reactors; and production of vehicle transmissions, special gear units for wind turbines, slide bearings, and couplings, as well as testing systems for the mobility sector. Its product range extends from low-consumption small cars to luxury class vehicles; and commercial vehicle sector ranges from pick-ups to buses and heavy trucks. The Financial Services division offers dealer and customer financing, leasing, banking and insurance, and fleet management services. The company provides its pro ducts under the Volkswagen, Audi, SEAT, ?KODA, Bentley, Bugatti, Lamborghini, Volkswagen Commercial Vehicles, Scania, and MAN brand names, as well as services under the Volkswagen Financial Services brand name. It operates primarily in Europe, North America, South America, and the Asia-Pacific. The company has strategic alliances with Dr. Ing. h.c. F. Porsche AG; Daimler AG; and Chrysler Group. Volkswagen Aktiengesellschaft was founded in 1937 and is headquartered in Wolfsburg, Germany.

Top Stocks To Invest In 2014: Eaton Vance Floating Rate Income Trust (EFT)

Eaton Vance Floating-Rate Income Trust is a closed-ended fixed income mutual fund launched and managed by Eaton Vance Management. The fund invests in fixed income markets of the United States. It invests in fixed income securities operating across diversified sectors. The fund primarily invests in senior, secured floating rate loans. It benchmarks the performance of its portfolio against the S&P/LSTA Leveraged Loan Index. Eaton Vance Floating-Rate Income Trust was formed on June 29, 2004 and is domiciled in the United States.

Top Stocks To Invest In 2014: Pendragon(PDG.L)

Pendragon PLC, together with its subsidiaries, operates franchised motor car dealerships in the United Kingdom and California. It sells new and used motor cars and motorbikes, as well as offers after sales services, body repairs, and parts sales under the Stratstone and Evans Halshaw brand names. The company also provides new and used trucks and commercial vehicles, as well as after sales services, body repairs, and parts sales under the Chatfields brand name. In addition, it offers Pinnacle, a Web enabled dealer management system with manufacturer interface and modules for vehicle sales and marketing, after sales, and bookkeeping and accounts generation to dealers and fleet operators under the Pinewood brand name; and software for the leasing, contract hire, fleet, and rental markets, as well as distributes parts under the Quickco brand name. Further, the company provides automotive fleet leasing and management facilities; contract hire services under the Pendragon Contra cts, Bramall Contracts, and Vardy Contract Motoring brand names; motor vehicle finance and insurance services; and management and marketing services, as well as involves in property holding activities. Pendragon PLC operates 245 franchise points. The company is based in Nottingham, the United Kingdom.

Top Stocks To Invest In 2014: Natural Gas(NG)

NovaGold Resources Inc., through its subsidiaries, engages in the exploration and development of mineral properties primarily in North America. The company primarily explores for gold, silver, copper, zinc, and lead ores. It holds interests in the Donlin Creek property covering 81,361 acres and the Ambler property comprising 90,614 acres located in Alaska; and the Galore Creek property comprising 293,838 acres located in northwestern British Columbia, Canada. The company was formerly known as NovaCan Mining Resources (1985) Limited and changed its name to NovaGold Resources Inc. in March 1987. NovaGold Resources Inc. was founded in 1984 and is based in Vancouver, Canada.

Advisors' Opinion:

• [By Monica Gerson]

  NovaGold Resources (NYSE: NG) is expected to post a Q3 loss at $0.03 per share.

  Premier Exhibitions (NASDAQ: PRXI) is projected to post its Q2 earnings.

• [By Holly LaFon] ref="http://www.gurufocus.com/StockBuy.php?GuruName=John+Paulson">John Paulson bough 20, 181,818 shares of NovaGold in the first quarter of 2010 at an average of $6 per share; he added 26,200 shares in the third quarter at an average of $9 per share, and 2,746,800 in the fourth quarter at an average of $9 per share. According to GuruFocus Real Time Picks, in February he increased this holding 30.49% and now owns 29,954,818 shares or 10.8% of the company.

  NovaGold Resources is a gold and copper company engaged in the exploration and development of mineral properties in Alaska and Western Canada. NovaGold has a market cap of $2.26 billion; its shares were traded at around $7.68 with and P/S ratio of 5622. NovaGold had an annual average earnings growth of 31.1% over the past 10 years.

  It is not a surprise that Paulson would increase his gold holdings. He said in his 2011 investor letter that ��y gold fund will top all others.��He added:

• [By Dan Caplinger]

  NovaGold Resources (NYSEMKT: NG  ) will give investors its quarterly report on Wednesday. But the mining company has already seen its stock plunge in the wake of crashing gold prices, and NovaGold earnings results aren't likely to give investors much good news barring a big surprise.

• [By Holly LaFon]

  He increased his holdings in gold companies in the fourth quarter accordingly. Gold stocks he found attractive in the fourth quarter are: Novagold Resources (NG), Randgold Resources (GOLD), Iamgold Corp. (IAG), Barrick Gold Corp. (ABX), Agnico Eagle (AEM) and International Tower Hill (THM).